Back to Journals » OncoTargets and Therapy » Volume 16

LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma [Retraction]

Authors Wang J , Gao J, Chen Q, Zou W, Yang F , Wei C, Wang Z 

Received 13 July 2023

Accepted for publication 13 July 2023

Published 19 July 2023 Volume 2023:16 Pages 615—616

DOI https://doi.org/10.2147/OTT.S430432



Wang J, Gao J, Chen Q, et al. Onco Targets Ther. 2020;13:9333–9347.

At the authors request, we the Editor and Publisher of OncoTargets and Therapy are retracting the published article. Concerns were raised to the authors attention regarding the duplication of images in Figures 2 and 5. Specifically,

  • Images from Figure 2E, Invasion, si-LINC1116 1# and si-LINC01116 2#, were duplicated.
  • Images from Figure 5E, Migration, Empty vector and Invasion, Empty vector and pcDNA-LINC0116 were duplicated.

The authors explained that errors had been made during the preparation of the figures, but no original data was provided to the journal. As verifying the validity of published work is core to the integrity of the scholarly record, the authors requested to retract the article. The editor agreed with this decision.

We have been informed in our decision-making by our editorial policies and the COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.


This retraction relates to this paper


Creative Commons License © 2023 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.